LCTX
AMEX · Biotechnology
Lineage Cell Therapeutics In
$1.45
-0.10 (-6.45%)
Financial Highlights (FY 2026)
Revenue
15.27M
Net Income
-66,623,906
Gross Margin
99.0%
Profit Margin
-436.5%
Rev Growth
-0.3%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 99.0% | 99.0% | 47.8% | 47.8% |
| Operating Margin | -251.6% | -226.4% | -28.4% | -27.0% |
| Profit Margin | -436.5% | -414.7% | -28.2% | -24.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 15.27M | 15.33M | 231.61M | 228.84M |
| Gross Profit | 15.12M | 15.17M | 110.75M | 109.43M |
| Operating Income | -38,426,092 | -34,697,986 | -65,786,728 | -61,682,578 |
| Net Income | -66,623,906 | -60,160,043 | -65,233,876 | -55,561,821 |
| Gross Margin | 99.0% | 99.0% | 47.8% | 47.8% |
| Operating Margin | -251.6% | -226.4% | -28.4% | -27.0% |
| Profit Margin | -436.5% | -414.7% | -28.2% | -24.3% |
| Rev Growth | -0.3% | -0.3% | -6.2% | +9.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 289.1K | 289.1K | 89.39M | 91.16M |
| Total Equity | 192.75M | 192.75M | 127.69M | 122.13M |
| D/E Ratio | 0.00 | 0.00 | 0.70 | 0.75 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -75,286,703 | -71,759,173 | -95,106,936 | -92,494,345 |
| Free Cash Flow | — | — | -33,113,271 | -35,128,048 |